upcoming glp-1 drugs Medicare Drug Coverage Comparing GLP‑1 Drugs With Other

Differential effects of glucagon-like peptide-1 on microvascular recruitment and glucose metabolism in short- and long-term insulin resistance

Supplementary Table 2, top), with close to zero consumption in the two higher dose levels (5 and 20 g/kg)

The research by drug maker Eli Lilly included people who used a CPAP machine to treat their obstructive sleep apnea, and those who didnt

Thus, we performed subgroup analyses to further investigate the differences in efficacy between various doses of each drug (appendix 14)

This meta-analysis, however, has some limitations owing to the limited number of referenced studies